Kick-starting the cancer-immunity cycle by targeting CD40
2015 (English)In: Oncoimmunology, ISSN 2162-402X, Vol. 4, no 7, e1011484Article in journal, Editorial material (Other academic) Published
Stimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and generate anticancer immunity is an attractive therapeutic approach. Since CD40 agonists exert their effects upstream of checkpoint inhibitors, including PD-1 or PD-L1 antagonists, they are ideal candidates for combination regimens.
Place, publisher, year, edition, pages
2015. Vol. 4, no 7, e1011484
CD40, PD-1, agonistic antibody, immunooncology
Immunology in the medical area Cancer and Oncology
IdentifiersURN: urn:nbn:se:uu:diva-258925DOI: 10.1080/2162402X.2015.1011484ISI: 000356964800002OAI: oai:DiVA.org:uu-258925DiVA: diva2:842667